Coya Therapeutics (NASDAQ:COYA) Upgraded by Roth Mkm to Strong-Buy Rating

Roth Mkm upgraded shares of Coya Therapeutics (NASDAQ:COYA) to a strong-buy rating in a research report released on Friday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Friday, April 10th. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Monday, April 20th. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Coya Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $4.42 on Friday. The firm has a market capitalization of $103.69 million, a price-to-earnings ratio of -3.84 and a beta of 0.62. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The stock has a fifty day moving average of $4.45 and a 200 day moving average of $4.90.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The company had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. Equities analysts forecast that Coya Therapeutics will post -1.5 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently bought and sold shares of COYA. Occudo Quantitative Strategies LP bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $66,000. CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $47,000. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics in the 3rd quarter valued at about $28,000. Cetera Investment Advisers lifted its stake in shares of Coya Therapeutics by 36.4% in the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after acquiring an additional 8,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Coya Therapeutics by 55.4% in the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after acquiring an additional 37,064 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.